doxorubicin

(redirected from Doxorubicin hydrochloride)
Also found in: Dictionary, Medical, Wikipedia.
  • noun

Words related to doxorubicin

an antibiotic used as an anticancer drug

References in periodicals archive ?
Doxorubicin hydrochloride liposome (an anti-cancer compound) under the commercial name of Sinadoxosome is the name of the drug presented by Exir Nano Sina Company in this year's festival.
The official NICE guidance recommends the use of pegylated liposomal doxorubicin hydrochloride (Caelyx(R)) as an option for the second-line treatment of women with partially platinum-sensitive, platinum-resistant or platinum-refractory advanced ovarian cancer, and for women who are allergic to platinum-based compounds[iv].
The current standard first-line treatment for the aggressive form of NHL is the CHOP chemotherapy combination, comprising the drugs cyclophosphamide, doxorubicin hydrochloride, Oncovin(R) (vincristine) and prednisone.
The new NICE guidance recommends the use of pegylated liposomal doxorubicin hydrochloride (Caelyx(R)) as an option for the second-line treatment of women who are partially platinum-sensitive (response between six- and 12-months), platinum-resistant or have platinum-refractory advanced ovarian cancer, and for women who are allergic to platinum-based compounds (v).
Anderson Cancer Center in Houston, Texas in which Onco TCS was used in combination with cyclophosphamide, doxorubicin hydrochloride, and prednisone.
Assistant Professor of Radiology, Department of Radiology, UCSF Medical Center, presented results of a multi-center, Phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers (MTC-DOX) in patients with hepatocellular carcinoma (HCC).
a targeted drug delivery company, today reported results of a multi-center, Phase I/II trial of hepatic intra-arterial delivery of doxorubicin hydrochloride adsorbed to magnetic targeted carriers (MTC-DOX) in patients with hepatocellular carcinoma.
DOXIl is a formulation of doxorubicin hydrochloride encapsulated in polyethylene glycol-coated liposomes.
DOXIL (doxorubicin HCl liposome injection), a long-circulating STEALTH liposome formulation of the widely prescribed anticancer drug doxorubicin hydrochloride, was developed and is owned by SEQUUS.
Contract award: "supply of anti-tumor medicinal product" doxorubicin hydrochloride powder for concentrate for solution for infusion "(liposomes) with atc code l01db01 for the needs of" sbaloz "eood, sofia paid by the budget of the" national health insurance fund.
DOXIL (pegylated-liposomal doxorubicin HCl) Injection, a long- circulating STEALTH(R) liposome formulation of the widely prescribed anticancer drug doxorubicin hydrochloride, was developed and is owned by SEQUUS.
DOXIL is a long-circulating STEALTH liposome formulation of the widely prescribed anticancer drug doxorubicin hydrochloride.
1255 list - code 668 igss - doxorubicin hydrochloride injectable solution or powder for parenteral use 10 mg vial or ampule.
DOXIL is SEQUUS' proprietary long-circulating STEALTH(R) liposome formulation of the widely prescribed anticancer drug doxorubicin hydrochloride.
DOX-SL is LTI's proprietary long-circulating Stealth(R) liposome formulation of the widely prescribed anti-cancer drug doxorubicin hydrochloride.